Press release
Ipca Laboratories awards PR mandate to Blue Lotus
Signs two year contract with its communications agencyMumbai, July 24, 2007: Blue Lotus has signed a two year contract with IPCA Laboratories, a publicly traded company, rated by Forbes as the Top 200 upcoming companies outside USA for three years in a row. IPCA was also rated by Business Today as the Top 200 most valuable companies in India.
Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca’s APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities. With operations in over 100 countries, exports account for over 53% of the company's income. From a modest income of Rs. 0.54 crores in 1975-76, the net income has soared to Rs. 921.24 crores in 2006-07 with exports accounting for Rs. 484.46 crores.
Elaborating on the new relationship, N. Chandramouli, CEO, Blue Lotus said, “We are extremely proud to be associated with IPCA Laboratories. The communications of IPCA will be unique since it uses a combination of pharma and finance to achieve the objectives of the client. Our existing strengths in these sectors have proven to be a dovetail fit for IPCA.”
Forbes, a leading US business magazine, selected Ipca in 2003 among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. Over 19,000 companies were considered by Forbes, and of the 18 companies from India that figured in this list, only four were from the 'Indian Pharmaceutical Sector'. Ipca happens to be one of them. Subsequently, Ipca was selected by FORBES in this prestigious list for two consecutive years; 2004 and 2005
Blue Lotus Communications is a 4-year old PR company based in Mumbai, India. Founded with the objective of providing creative PR, Blue Lotus emphasizes on knowledge, passion, continuous learning, and client experience. With specializations in Technology, Healthcare, Finance and Brands, the agency has a list of over 40 marquee retainer clients. Some of the Blue lotus accounts include Dun & Bradstreet, Sharekhan, Trend Micro, YOU Broadband, and Johnson & Johnson among many others.
Media RSVP
Mrs Chitra Shripad +91 98234 42065
chitra@bluelotuspr.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ipca Laboratories awards PR mandate to Blue Lotus here
News-ID: 24600 • Views: …
More Releases from Blue Saints
139 - Indian Railways Tele-helpline Celebrates First Anniversary
Registers five Lakh calls in a day, expects to touch 20 lakh calls per day by end of the year.
Pune, 18 July 2008: “139 - Rail Sampark”, the national enquiry for Indian Railways successfully completed its first year of operations today. The service has expanded significantly registering over 5 lakhs calls in a day from across the country. The service was launched last year for North Zone, by the Hon’ble…
HR symposium stresses on the need to let employees experiment
India, October, 2007: “The National HR – Symposium”a first of its kind was held to discuss the HR needs in the light of India’s emergence as an economic powerhouse in the new millennium is scripted largely by its globally-acknowledged human resources. As the nation prepares for double-digit GDP growth in the 11th Plan period (2007-12), the spotlight is on the role of human resources in driving India’s growth and global…
3M Healthcare Appoints Blue Lotus as Communications Partner
Mumbai, 19th Sept 07: The healthcare business division of 3M India Ltd. has appointed Blue Lotus communications to handle the PR communications mandate for the division. 3M India Ltd. is the Indian arm of 3M and has been in India for the last 19 years and markets about 2000 products in the country.
The 3M Healthcare is a leading provider of medical, dental & orthodontic, drug delivery products & solutions and…
More Releases for IPCA
Hydroxychloroquine Market - Expectations & Growth Trends Highlighted until 2030 …
Latest research findings from Market Industry Reports (MIR) report titled "Hydroxychloroquine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030." Suggests that the global hydroxychloroquine market is expected to witness substantial CAGR from 2020 to 2030.?
The market growth can be attributed to several factors, which has led toits wide-scale adoption. Growing prevalence of malaria and increasing demand of hydroxychloroquine drug worldwide for the treatment of COVID-19are anticipated…
Global Atenolol Market 2018-2023 Ipca, Chifeng Arker, KOPRAN, Teva
The research report “Atenolol Market Report 2018-2023” offers comprehensive knowledge on the Atenolol market. It analyses the important factors of the Atenolol based on present industry situations, Atenolol demands, business strategies utilized by Atenolol players and the future prospects from various angles in detail.
Industry analysis is a market assessment tool used by business and analysts to understand the complexity of an industry. Optical Pulse Sensor Market report It helps…
Global Atenolol Market 2017 - KOPRAN, AMRI, Ipca, CFM
Global Atenolol market Report offers decisive insights into the overall Atenolol industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Atenolol industry segments based on the type of applications, type of product Components and services, and different geographical regions.
Atenolol is a selective ß1 receptor antagonist, a drug belonging to the group of beta blockers (sometimes…
Global Atenolol Market 2016 - KOPRAN, Ipca, Teva
The report that is written on the titled Atenolol Market 2016 covers all the aspects of the global market study. This report has an estimation about the Atenolol Market size in terms of value (US$). The report contains the broad segmentation of the market. The report provides the information about the Atenolol Market and also forecasts its position in the coming years.
Atenolol is a selective ß1 receptor antagonist, a…
Drugs for Malaria Market 2017- Cipla, Guilin Pharmaceutical, IPCA Laboratories
Drugs for Malaria Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors.
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a…
Global Drugs for Malaria Market 2017 - Cipla, Guilin Pharmaceutical, IPCA Labora …
The report published on the Drugs for Malaria market provides an analytical view of the Drugs for Malaria industry’s performance in the global scenario. In a detailed chapter-wise format, the study evaluates the numerous aspects corresponding to the global Drugs for Malaria market. To begin with, the market definition, applications, classification, and industry value chain structure is included in the report, to update stakeholders on incumbent market dynamics. Development trends…
